Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
AstraZeneca
Baxter
Medtronic

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DALOTUZUMAB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Dalotuzumab

Trial ID Title Status Sponsor Phase Summary
NCT00614393 Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004 AM9) Completed Merck Sharp & Dohme Corp. Phase 2 This study will compare how well dalotuzumab in combination with cetuximab and irinotecan works in treating patients with wild type KRAS metastatic colorectal cancer compared to how well cetuximab and irinotecan work alone.
NCT00654420 A Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (0646-007) Completed Merck Sharp & Dohme Corp. Phase 2 This study will look for the highest tolerated dose of dalotuzumab given in combination with erlotinib. The study will also investigate how well dalotuzumab works in conjunction with erlotinib at treating recurrent non-small cell lung cancer.
NCT00729742 Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) Completed Merck Sharp & Dohme Corp. Phase 1 This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
NCT00730379 A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) Completed Ariad Pharmaceuticals Phase 1 This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.
NCT00730379 A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) Completed Merck Sharp & Dohme Corp. Phase 1 This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Dalotuzumab

Condition Name

Condition Name for
Intervention Trials
Breast Cancer 3
Lung Cancer 1
Colorectal Cancer 1
Solid Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Breast Neoplasms 4
Carcinoma, Non-Small-Cell Lung 3
Colorectal Neoplasms 2
Rectal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dalotuzumab

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 6
Phase 1 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 10
Terminated 1
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dalotuzumab

Sponsor Name

Sponsor Name for
Sponsor Trials
Merck Sharp & Dohme Corp. 12
Ariad Pharmaceuticals 1
Alliance for Clinical Trials in Oncology 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 13
Other 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Harvard Business School
AstraZeneca
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.